Patents
Literature
5 results about "Genetic vaccination" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Vaccines at Work. The merits of genetic immunization become most apparent when the actions of traditional vaccines are understood. Traditional preparations consist primarily of a killed or a weakened version of a pathogen (disease-causing agent) or of some piece (subunit) of the agent.
Artificial nucleic acid molecules for improved protein or peptide expression
The invention relates to an artificial nucleic acid molecule comprising at least one 5′ UTR element which is derived from a TOP gene, at least one open reading frame, and preferably at least one histone stem-loop. Optionally the artificial nucleic acid molecule may further comprise, e.g. a poly(A)sequence, a poyladenylation signal, and / or a 3′ UTR. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and / or genetic vaccination.
Owner:CUREVAC SE
Artificial nucleic acid molecules
The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3-untranslated region element (3′-UTR element) and / or at least one 5-untranslated region element (5′-UTR element), wherein said artificial nucleic acid molecule is characterized by high translation efficiency. The translation efficiency is contributed, at least in part, by the 5′-UTR element or the 3′-UTR element, or both of the 5′-UTR element and the 3′-UTR element. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and / or genetic vaccination. Furthermore, novel 3′-UTR elements and 5′-UTR elements are provided.
Owner:CUREVAC SE
Engineered mRNA and use thereof
Provided are an engineered mRNA and a method for improving protein expression using same. Also provided is the use of such engineered mRNA in gene therapy and / or genetic vaccination.
Owner:XIANWEI (HAINAN) BIOTECHNOLOGY CO LTD
Carbocyclic nucleoside, oligonucleotide, preparation method therefor, and medical uses thereof
PCT designated stage expiredWO2025015676A1Sugar derivativesActivity regulationNucleotideSingle strand
Disclosed in the present invention are a carbocyclic nucleoside, an oligonucleotide, a preparation method therefor, and medical uses thereof. The carbocyclic nucleoside is a compound or salt represented by formula (I). The carbocyclic nucleoside or oligonucleotide of the present invention is used in the preparation of a drug used for gene therapy, genetic vaccination, antisense therapy, interfering RNA, or nucleic acid transfer. The oligonucleotide of the present invention has high binding affinity to single-stranded RNA, and has nuclease resistance and plasma stability.
Owner:REDFIELD PHARMACEUTICAL INC +1
Artificial nucleic acid molecules for improved protein or peptide expression
The invention relates to an artificial nucleic acid molecule comprising at least one 5′UTR element which is derived from a TOP gene, at least one open reading frame, and preferably at least one histone stem-loop. Optionally the artificial nucleic acid molecule may further comprise, e.g. a poly(A)sequence, a poyladenylation signal, and / or a 3′UTR. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and / or genetic vaccination.
Owner:CUREVAC SE